Status:
TERMINATED
Vitamin E Treatment for Long-Chain 3-Hydroxyacyl Coenzyme A (CoA) Dehydrogenase (LCHAD) Associated Neuropathy
Lead Sponsor:
Oregon Health and Science University
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Oregon State University
Conditions:
Peripheral Neuropathy
Mitochondrial Trifunctional Protein Deficiency
Eligibility:
All Genders
7+ years
Phase:
NA
Brief Summary
Purpose: People with a genetic defect in the ability to burn fat can also develop a problem with the nerves in their feet. The nerve problem, or neuropathy, can limit their ability to walk. Part of t...
Detailed Description
People with long-chain 3-hydroxyacyl CoA dehydrogenase (LCHAD) or mitochondrial trifunctional protein (TFP) deficiency, inherited disorders of fatty acid ß-oxidation, lack an ability to fully oxidize ...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of TFP, or LCHAD deficiency and progressive peripheral neuropathy
- Subjects must be \> 7 years of age, and be willing to take vitamin E supplements.
Exclusion
- None
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00840112
Start Date
July 1 2010
End Date
October 1 2015
Last Update
October 21 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health and Sciences University
Portland, Oregon, United States, 97239